Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$269.52 USD
-0.94 (-0.35%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $269.74 +0.22 (0.08%) 7:38 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
ALNY 269.52 -0.94(-0.35%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Alnylam (ALNY) Reports Q2 Earnings: What Key Metrics Have to Say
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
Other News for ALNY
The 3 Best Gene Editing Stocks to Buy in August 2024
Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran? in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Maintaining Hold: Balancing Alnylam’s Strong Quarterly Results Against Market Expectations and Potential Risks
Alnylam price target raised by $33 at Raymond James, here's why